Dae Gon Ha
Stock Analyst at Stifel
(2.67)
# 1,957
Out of 5,115 analysts
54
Total ratings
38.46%
Success rate
8.84%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $92 → $98 | $80.70 | +21.44% | 5 | Dec 16, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.41 | +269.69% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.21 | +35.75% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $49.11 | +50.68% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $12.01 | -75.02% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $9.59 | +567.36% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $251.29 | -12.45% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $34.58 | +267.26% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.51 | +1,267.52% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.57 | +404.20% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.61 | +334.78% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.25 | +407.32% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $112.27 | -77.73% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.25 | +12.28% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $22.90 | +1,144.81% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.19 | +813.24% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.43 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $25.16 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.70 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.14 | +952.63% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $18.97 | +2,483.03% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Dec 16, 2025
Maintains: Buy
Price Target: $92 → $98
Current: $80.70
Upside: +21.44%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.41
Upside: +269.69%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.21
Upside: +35.75%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $49.11
Upside: +50.68%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $12.01
Upside: -75.02%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $9.59
Upside: +567.36%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $251.29
Upside: -12.45%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $34.58
Upside: +267.26%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.51
Upside: +1,267.52%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.57
Upside: +404.20%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.61
Upside: +334.78%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.25
Upside: +407.32%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $112.27
Upside: -77.73%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.25
Upside: +12.28%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $22.90
Upside: +1,144.81%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.19
Upside: +813.24%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.43
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $25.16
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.70
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.14
Upside: +952.63%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $18.97
Upside: +2,483.03%